CStone Pharmaceuticals (STU:PH4) DeferredTaxAndRevenue: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PH4 CStone Pharmaceuticals STU:PH4
40 GF Score
Price €0.51
GF Value €0.12
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is CStone Pharmaceuticals DeferredTaxAndRevenue?

CStone Pharmaceuticals STU:PH4 -0.39% 40 DeferredTaxAndRevenue is €0.00 Mil as of Dec. 2025. GuruFocus rates STU:PH4 with a GF Score™ of 40/100 and a GF Value™ of €0.12 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

CStone Pharmaceuticals's current deferred tax and revenue for the quarter that ended in Dec. 2025 was €0.00 Mil.

CStone Pharmaceuticals DeferredTaxAndRevenue Related Terms

CStone Pharmaceuticals DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for CStone Pharmaceuticals's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CStone Pharmaceuticals DeferredTaxAndRevenue Chart

CStone Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CStone Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:PH4
40GF Score
CStone Pharmaceuticals STU:PH4
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of €0.00 Mil mean?
CStone Pharmaceuticals (STU:PH4) has a DeferredTaxAndRevenue of €0.00 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on CStone Pharmaceuticals.
Is CStone Pharmaceuticals' DeferredTaxAndRevenue too high?
CStone Pharmaceuticals' current DeferredTaxAndRevenue is €0.00 Mil. Overall, CStone Pharmaceuticals has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CStone Pharmaceuticals' DeferredTaxAndRevenue compare to VRTX and REGN?
CStone Pharmaceuticals' DeferredTaxAndRevenue of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on CStone Pharmaceuticals. CStone Pharmaceuticals's current DeferredTaxAndRevenue is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CStone Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CStone Pharmaceuticals (STU:PH4) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.12, compared to a current price of €0.51 — trading 323% above its estimated fair value. The current DeferredTaxAndRevenue is €0.00 Mil. CStone Pharmaceuticals' overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For CStone Pharmaceuticals (STU:PH4), the current DeferredTaxAndRevenue is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CStone Pharmaceuticals (STU:PH4) Overvalued in 2026?

Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued. The current stock price of €0.51 is trading 323% above its estimated GF Value™ of €0.12. GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:PH4:

  • DeferredTaxAndRevenue: €0.00 Mil
  • GF Value™: €0.12 vs. price of €0.51 (323% above fair value)
  • GF Score™: 40/100 with 7 warning signs

No single metric tells the full story. See the STU:PH4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CStone Pharmaceuticals Business Description

Other Exchanges CSPHF:USA02616:Hong Kong
Address 218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Suzhou, CHN, 215123
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
40GF Score

Get the complete analysis for STU:PH4

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price
€0.12
GF Value